Financing - March 28, 2022
SynAct resolves on a fully guaranteed rights issue of 150 MSEK
The Board of Directors of SynAct Pharma has resolved to carry out a new issue of shares with preferential rights for existing shareholders of approximately 150 million SEK before issue costs, guaranteed to 100 percent. In addition, the Board of Directors may, based on the authorization granted by the annual general meeting on 21 May […]
Financing - March 25, 2022
Outcome in AlzeCure’s rights issue
AlzeCure Pharma has announced the outcome of the rights issue with preferential rights for the shareholders that ended on March 22, 2022. The subscription breakdown show that approximately 59.4 percent was subscribed with and without the exercise of subscription rights. Consequently underwriters of the Rights Issue will be allocated approximately 20.8 percent of the Rights […]
Financing - March 23, 2022
QureTech Bio receives support from ENABLE-2
The company receives support from the Swedish Research Council’s major investment ENABLE-2, which in collaboration with Vinnova gives small and medium-sized companies access to the ENABLE-2 platform to continue development of new antibiotics. QureTech Bio is developing new drugs that either enhance the existing effects of antibiotics or disarm bacteria instead of killing them, thereby […]
Biotech Business - March 17, 2022
Ilya Pharma closes 8.5 million EUR funding round
Ilya Pharma has closed a 8.5 million EUR funding round where the EIC Fund participated and was joined by an international consortium of family offices and private investors. “I believe Ilya is at the forefront of science by developing what can be the next advancement in biologics, tissue regeneration and immunology. The management’s decision to […]
Financing - March 16, 2022
SyntheticMR carries out directed share issue of 60 MSEK
The Board of Directors of SyntheticMR has resolved to carry out a directed new issue of 1,250,000 shares, at a subscription price of SEK 48 per share, entailing proceeds of SEK 60 million before transaction costs. The Directed Share Issue was oversubscribed and a number of Swedish and international institutional investors, including certain existing shareholders, […]
Financing - March 16, 2022
Gilde Healthcare raises 500 million EUR for private equity investments
Gilde Healthcare has raised 517 million EUR towards the first and final close of Gilde Healthcare Private Equity IV (GHPE IV). GHPE IV focuses on investments in profitable healthcare companies operating in the lower mid-market in North-west Europe. The fund concentrates on firms with an active buy-and-build strategy and invests in all sub-segments of the […]
